培美曲塞+顺铂和吉西他滨+顺铂治疗晚期肺腺癌的临床疗效

Effect of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Advanced Lung Adenocarcinoma

目的：探讨培美曲塞或吉西他滨＋顺铂治疗晚期肺腺癌的疗效和毒副作用。方法：64例晚期肺腺癌患者分为培美曲塞＋顺铂（28例。培美曲塞500 mg/m2,第1 d,顺铂25 mg/m2,第1~3 d）和吉西他滨＋顺铂（36例。吉西他滨1 000 mg/m2,第1d及第8 d,顺铂25 mg/m2,第1~3 d）组,治疗周期21 d。结果：培美曲塞、吉西他滨＋顺铂组总有效率分别为32.1%和27.8%,中位无疾病进展时间6.7和6.3个月,中位生存期16.0和13.8个月。培美曲塞＋顺铂组WBC减少、血小板降低明显低于吉西他滨＋顺铂组（P〈0.05）。结论：培美曲塞＋顺铂可作为初治晚期肺腺癌安全有效的药物。

Objective：To explore the efficacy and side effects of pemetrexed or gemcitabine combined with cisplatin in the treatment of advanced lung adenocarcinoma. Methods：Sixty-four patients with advanced lung adenocarcinoma were divided into pemetrexed combined with cisplatin group（28 case. Pemetrexed 500 mg/m2 iv infusion d1,cisplatin 25 mg/m2 iv infusion d1~3）and gemcitabine combined with cisplatin group（36 cases. Gemcitabine 1 000 mg/m2 iv infusion d1,8,cisplatin 25 mg/m2 iv infusion d1~3）. The treatment cycle was 21 days. Results：The total effective rate in the pemetrexed＋cisplatin group was 32.1%,27.8% of gemcitabine＋cisplatin group. The median progression free survival in the pemetrexed＋cisplatin group was 6.7 months,6.3 months of gemcitabine＋cisplatin group. The median survival time in the pemetrexed＋cisplatin group was 16.0 months,13.8 months of gemcitabine＋cisplatin group. The white blood cell reduction and lower platelet count in the pemetrexed＋cisplatin group were significantly lower than those in the gemcitabine＋cisplatin group（P0.05）. Conclusion ： Pemetrexed＋cisplatin can be used as a safe and effective drug for advanced lung adenocarcinoma.